The AudioNotch Tinnitus Treatment Blog

AM101, a drug for treating the acute development of tinnitus, is entering Phase 3 clinical trials. 

Auris Medical today announced enrollment of the first patient into the TACTT21 clinical trial. This phase 3 trial will evaluate the efficacy, safety and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media. TACTT2 will enroll 330 patients at more than 60 sites primarily in the United States and Canada.

The initiation of the TACTT2 trial follows shortly after the start of TACTT3, its European counterpart. Both have been … Continue Reading